RE: New RNS.15 Oct 2024 15:17
The reverse of this one would be good... from £1 to 1p since his appointment, now that takes alot of effort over 4.5 years
Posted on 25th March 2020 - RSA News
Following a successful global search, The RSA Group is pleased to announce the placement of Dr Jon Burrows as the new Chief Executive Officer at Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of biomarkers.
Dr Burrows brings over 25 years of industry experience with an established track record in oncology and personalized medicine within big pharma, biotech and molecular diagnostics companies. He is the co-founder of Oncology Partners, a consulting and clinical advisory firm focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies. Previously, Jon was President and CEO of OncoPlex Diagnostics, a leader in clinical proteomics for oncology. Under Jon’s leadership OncoPlex was transformed from a private, pre-revenue stage company into a thriving clinical diagnostics business with marketed products, which was ultimately acquired by NantOmics in May 2015. From 2007 to 2009, he was Director of Business Development and Interim Head of the Translational Diagnostics Business Unit at Ventana Medical Systems, and subsequently Director of Pharma Operations at Roche, following the $3.4 billion acquisition of Ventana Medical Systems by Roche in 2008. His early career was in oncology drug development and the development of molecular diagnostics for precision medicine.
Jon will lead the company from a base in Maryland, USA, a location which will help OBD to further expand its US presence.
Sign In
Follow the stocks
